Publicacións en colaboración con investigadores/as de Clínica Universitaria de Navarra (4)

2019

  1. Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (Scientific Reports, (2019), 9, 1, (2589), 10.1038/s41598-019-39291-2)

    Scientific Reports

  2. Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

    Scientific Reports, Vol. 9, Núm. 1

2016

  1. SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016)

    Clinical and Translational Oncology, Vol. 18, Núm. 12, pp. 1237-1242

2010

  1. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: A phase 2 study (SOGUG-02-06)

    The Lancet Oncology, Vol. 11, Núm. 4, pp. 350-357